Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation

Current Opinion in Organ Transplantation

Volumn 20, Issue 1, 2015, Pages 79-85

  Cortinovis, Monica ^a   Casiraghi, Federica ^a   Remuzzi, Giuseppe ^a   Perico, Norberto ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

alloreactive donor specific memory T cells; mesenchymal stromal cells; organ transplantation; transplantation tolerance

Indexed keywords

BASILIXIMAB; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; GLIADIN; INTERLEUKIN 10; INTERLEUKIN 17; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYELIN; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; EFFECTOR CELL; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MESENCHYMAL STROMA CELL; MULTIPOTENT STEM CELL; NONHUMAN; ORGAN DONOR; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TRANSPLANTATION TOLERANCE; ANIMAL; CYTOLOGY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; ORGAN TRANSPLANTATION; T LYMPHOCYTE;

ANIMALS; HUMANS; IMMUNOLOGIC MEMORY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE;

EID: 84921415683     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000145     Document Type: Review

References (53)

1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-Term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11:450-462.
2. Sayegh MH, Remuzzi G. Clinical update: immunosuppression minimisation. Lancet 2007; 369:1676-1678.
3. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172:603-606.
4. Sykes M, Szot GL, Swenson KA, et al. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3:783-787.
5. Durham MM, Bingaman AW, Adams AB, et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165:1-4.
6. Ford ML, Larsen CP. Transplantation tolerance: memories that haunt us. Sci Transl Med 2011; 3:86s22.
7. Nadazdin O, Boskovic S, Murakami T, et al. Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Sci Transl Med 2011; 3:86ra51.
8. Bestard O, Cruzado JM, Lucia M, et al. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int 2013; 84:1226-1236.
9. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163:2267-2275.
10. Augustine JJ, Siu DS, Clemente MJ, et al. Pretransplant IFN-gamma ELISPOTs are associated with posttransplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5:1971-1975.
11. Page AJ, Ford ML, Kirk AD. Memory T-cell-specific therapeutics in organ transplantation. Curr Opin Organ Transplant 2009; 14:643-649.
12. Krummey SM, Ford ML. Heterogeneity within T cell memory: implications for transplant tolerance. Front Immunol 2012; 3:36.
13. Duffy MM, Ritter T, Ceredig R, et al. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2:34.
14. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101:3722-3729.
15. Reading JL, Yang JH, Sabbah S, et al. Clinical-grade multipotent adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and autoimmunity. J Immunol 2013; 190:4542-4552.
16. English K, Ryan JM, Tobin L, et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play nonredundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156:149-160.
17. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815-1822.
18. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 2014; 14:24-35.
19. Li XC, Kloc M, Ghobrial RM. Memory T cells in transplantation: progress and challenges. Curr Opin Organ Transplant 2013; 18:387-392.
20. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10:87-92.
21. Gallon L, Gagliardini E, Benigni A, et al. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H). Clin J Am Soc Nephrol 2006; 1:539-545.
22. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18:1007-1018.
23. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5:465-474.
24. Afzali B, Mitchell PJ, Scotta C, et al. Relative resistance of human CD4+ memory T cells to suppression by CD4+ CD25+ regulatory T cells. Am J Transplant 2011; 11:1734-1742.
25. Yang J, Brook MO, Carvalho-Gaspar M, et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A 2007; 104:19954-19959.
26. Zhai Y, Meng L, Gao F, et al. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol 2002; 169:4667-4673.
27. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-1895.
28. Poggio ED, Augustine JJ. Alloreactive T cells and 'the persistence of memory'. Kidney Int 2013; 84:1074-1076.
29. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-317.
30. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970; 3:393-403.
31. Campagnoli C, Roberts IA, Kumar S, et al. Identification of mesenchymal stem/progenitor cells in human first-Trimester fetal blood, liver, and bone marrow. Blood 2001; 98:2396-2402.
32. Di Ianni M, Del Papa B, De Ioanni M, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36:309-318.
33. Han KH, Ro H, Hong JH, et al. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. Transpl Immunol 2011; 25:7-15.
34. Karlsson H, Samarasinghe S, Ball LM, et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008; 112:532-541.
35. Engela AU, Baan CC, Litjens NH, et al. Mesenchymal stem cells control alloreactive CD8+ CD28-T cells. Clin Exp Immunol 2013; 174:449-458.
36. Ciccocioppo R, Camarca A, Cangemi GC, et al. Tolerogenic effect of mesenchymal stromal cells on gliadin-specific T lymphocytes in celiac disease. Cytotherapy 2014; 16:1080-1091.
37. Zafranskaya MM, Nizheharodova DB, Yurkevich MY, et al. In vitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients. Immunol Lett 2013; 149:9-18.
38. Zafranskaya M, Nizheharodava D, Yurkevich M, et al. PGE2 contributes to in vitro MSC-mediated inhibition of nonspecific and antigen-specific T cell proliferation in MS patients. Scand J Immunol 2013; 78:455-462.
39. Favaro E, Carpanetto A, Lamorte S, et al. Human mesenchymal stem cellderived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. Diabetologia 2014; 57:1664-1673.
40. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181:3933-3946.
41. Eggenhofer E, Benseler V, Kroemer A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3:297.
42. Fierabracci A, Del Fattore A, Luciano R, et al. Recent advances in mesenchymal stem cell immunomodulation. The role of microvesicles. Cell Transplant 2013. [Epub ahead of print]
43. Casiraghi F, Azzollini N, Todeschini M, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012; 12:2373-2383.
44. Oura T, Hotta K, Cosimi G, et al. Suppression of CD8+ memory T cell proliferation and expansion of T regulatory cells by bone marrow derived autologous mesenchymal stem cells in nonhuman primates [Abstract]. Am J Transplant 2014; 14:43; S3: Abstract 2274.
45. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307:1169-1177.
46. Reinders ME, de Fijter JW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2013; 2:107-111.
47. Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6:412-422.
48. Perico N, Casiraghi F, Gotti E, et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int 2013; 26:867-878.
49. Mudrabettu C, Kumar V, Rakha A, et al. Safety and efficacy of autologous mesenchymal stromal cells transplantation in patients undergoing living donor kidney transplantation: a pilot study. Nephrology (Carlton) 2014. [Epub ahead of print]
50. Peng Y, Ke M, Xu L, et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 2013; 95:161-168.
51. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8:2086-2096.
52. Jitschin R,Mougiakakos D, Von Bahr L, et al. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells 2013; 31:1715-1725.
53. Dander E, Lucchini G, Vinci P, et al. Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Leukemia 2012; 26:1681-1684.